Villarrubia R, Oyagüez I, Alvarez-Roman MT, Mingot-Castellano ME, Parra R, Casado MA
Cost analysis of prophylaxis with activated prothrombin complex concéntrate versus on-demand therapy with activated factor VII in severe hemophilia A patients with inhibitors, in Spain
Haemophilia. 2015;21(3):320-9
Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G
Impact of dynamic microbiological environment on the clinical efficacy of ertapenem and piperacillin/tazobactam in the treatment of complicated community-acquired intra-abdominal infection in Spain: A cost-consequence analysis
Appl Health Econ Health Policy. 2015;13(4):369-79
Arevalo JM, Lozano V, Oyagüez I, Casado MA
Surgical treatment of pressure ulcers with a fibrin sealant in patients with spinal cord injury: A cost-consequence analysis
Adv Skin Wound Care. 2015;28(11):503-7
Lago J, Argudo S, Burneo M, Cuadrado M, Turégano F, Casado A
The systematic use of fibrin-based biological adhesive to prevent leakage due to healing defects in rectal anastomosis significantly reduces costs
J Surgery. 2015;3(2):12-7
Solé A, Poveda JL, Girón R, Prados C, De Gracia J, Casado MA
Economic Impact linked to the reduction of exacerbations when a treatment regime with inhaled antibiotics is switched to aztreonam lysine in patients with cystic fibrosis and chronic pulmonary infection caused by Pseudomonas aeruginosa
17th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Amsterdam, Holland. 8-12 nov 2014
Ariza R, van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, Janssen K
Análisis de minimización de costes de abatacept subcutáneo en el tratamiento de la artritis reumatoide en España
Farm Hosp. 2014;38(4):257-65
De Andrés-Nogales F, Morell A, Aracil J, Torres C, Oyagüez I, Casado MA
Análisis de costes del uso de toxina botulínica A en España
Farm Hosp. 2014;38(3):193-201
Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G
Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain
ClinicoEcon Outcomes Res. 2014;6:83–92
Torres C, Oyagüez I, Lozano I, Pericay C, Pàmpols M, Casado MA